Business context and reporting period
The supplied filing is Rexahn Pharmaceuticals, Inc.’s Form 10-K for the fiscal year ended December 31, 2014—not an Opus Genetics filing or a 2014 Q4 report. The company describes itself as a clinical-stage biopharmaceutical developer focused primarily on oncology. Its active pipeline included Archexin in Phase IIa, RX-3117 in Phase Ib and Supinoxin in Phase I; Archexin-Nano and RX-21101 were preclinical. Serdaxin and Zoraxel were not being actively developed.
Financial performance and liquidity
| Metric | 2014 | 2013 |
|---|---|---|
| Revenue | $0 | $0 |
| General and administrative expense | $6.25 million | $4.73 million |
| Research and development expense | $7.02 million | $3.25 million |
| Operating loss | $13.27 million | $7.98 million |
| Net loss | $18.52 million | $9.50 million |
| Net loss per share | $0.11 | $0.07 |
| Cash used in operating activities | $11.04 million | $7.98 million |
| Cash and cash equivalents at year-end | $9.83 million | $18.69 million |
| Marketable securities at year-end | $22.87 million | $0.10 million |
Cash and marketable securities totaled approximately $32.70 million at December 31, 2014. Current assets were $33.43 million and current liabilities were $6.95 million. Total liabilities were $6.95 million, including $3.77 million of warrant liabilities; the balance sheet shows no conventional borrowings. The filing reports no product revenue, so operating margins are not meaningful. The company reported an accumulated deficit of $91.33 million.
Changes versus the prior year
- Net loss increased approximately 95% year over year; R&D expense more than doubled as clinical programs advanced, and G&A increased 32%.
- Cash used in operations rose from $7.98 million to $11.04 million. Year-end cash declined, while marketable securities increased substantially after the 2014 financing and investment of funds.
- The 2014 net loss included a $5.18 million noncash unrealized warrant fair-value loss, compared with $1.37 million in 2013. The company attributed the increase primarily to a higher common-stock price.
- Financing provided $24.84 million of cash in 2014, including net proceeds of $18.63 million from a January registered direct offering and $5.95 million from warrant exercises.
Outlook, commentary and risks
- Management said cash, cash equivalents and marketable securities were expected to fund current activities for at least 12 months. The company nevertheless stated it would need additional capital to continue development and could reduce R&D if financing were insufficient.
- For 2015, Rexahn expected higher expenses for Archexin, RX-3117 and Supinoxin as trials continued; preclinical-program expenses were expected to remain broadly flat. It targeted completion of the Archexin RCC initial safety component in the second half of 2015 and expected RX-3117 enrollment and the Supinoxin trial to progress or conclude in the first half of 2015.
- RX-3117 and Supinoxin had not reached their maximum tolerated doses. Their early safety and tolerability observations are not evidence of efficacy or approval. Archexin’s pancreatic-cancer Phase IIa report cited median survival of 9.1 months versus 5.65 months from historical gemcitabine data; this was not a randomized comparison.
- On March 16, 2015, after year-end, the company entered an at-the-market sales agreement permitting up to $40 million of common-stock sales; no shares had been sold under it as of the filing. Potential sales could dilute existing shareholders.
- Major risks include clinical-trial failure or delay, regulatory uncertainty, reliance on contract research organizations and manufacturers, lack of product revenue and ongoing funding needs, competition, intellectual-property challenges, and uncertain future coverage and reimbursement. A Japan patent dispute concerning Supinoxin was disclosed. Estimated remaining costs under R&D service agreements were approximately $8.44 million at year-end.
- The independent auditor issued an unqualified opinion on the financial statements and internal controls. Management stated disclosure controls and internal control over financial reporting were effective as of year-end.
Most important facts to verify
- Confirm the filing identity and period: the source is Rexahn Pharmaceuticals’ 2014 Form 10-K, not Opus Genetics’ filing.
- Review the complete financial statements and notes for cash runway assumptions, warrant accounting and liquidity needs.
- Check subsequent filings for ATM share sales, additional financing, and resulting dilution.
- Verify current status and results of the Archexin, RX-3117 and Supinoxin clinical programs against trial disclosures.
- Assess the status of the Supinoxin Japanese patent proceeding and the company’s other key patent protections.